Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system
- PMID: 22565090
- DOI: 10.1016/j.pharmthera.2012.04.003
Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system
Abstract
Cardiovascular disease is the leading cause of death in people with severe mental disorders, and rates are proportionally greater than for other diseases such as cancer. Reports of sudden death in patients receiving antipsychotic treatment have raised concerns about the safety of antipsychotic drugs, leading to a number of recent changes in how such drugs are advertised and marketed. The majority of second generation antipsychotic drugs also have significant metabolic side-effects, such as weight gain, insulin resistance and hyperlipidemia, which may contribute indirectly to cardiovascular complications. As the use of antipsychotic drugs continues to expand into new indications and populations such as children and adolescents, a better understanding is needed of how antipsychotic drugs affect the cardiovascular system. Antipsychotic drugs interact with numerous receptors both centrally and peripherally, including monoamine receptors. The direct, non-specific pharmacological actions of antipsychotic drugs can lead to adverse cardiovascular effects, including orthostatic hypotension, tachycardia and ventricular arrhythmias. The mechanisms responsible for these antipsychotic-induced cardiovascular abnormalities have not been fully elucidated, but likely involve blockade of adrenergic or cholinergic receptors and hERG channels, in addition to impaired autonomic function. The direct and indirect effects of antipsychotic drugs on the cardiovascular system and their possible mechanisms of action are discussed in this review, where both preclinical and clinical findings are integrated.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. Encephale. 2009. PMID: 19748369 French.
-
[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].Encephale. 2002 Nov-Dec;28(6 Pt 1):552-62. Encephale. 2002. PMID: 12506268 French.
-
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.Pharmacopsychiatry. 2002 Nov;35(6):205-19. doi: 10.1055/s-2002-36391. Pharmacopsychiatry. 2002. PMID: 12518268 Review.
-
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Mol Psychiatry. 2008 Jan;13(1):27-35. doi: 10.1038/sj.mp.4002066. Epub 2007 Sep 11. Mol Psychiatry. 2008. PMID: 17848919 Review.
-
Cardiovascular effects of antipsychotics.Expert Rev Neurother. 2007 Jul;7(7):829-39. doi: 10.1586/14737175.7.7.829. Expert Rev Neurother. 2007. PMID: 17610390 Review.
Cited by
-
Fluphenazine decanoate-induced bradycardia: A case report.Neuropsychopharmacol Rep. 2022 Sep;42(3):368-373. doi: 10.1002/npr2.12251. Epub 2022 Apr 3. Neuropsychopharmacol Rep. 2022. PMID: 35373519 Free PMC article.
-
Inhibitory effects of the atypical antipsychotic, clozapine, on voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.Korean J Physiol Pharmacol. 2022 Jul 1;26(4):277-285. doi: 10.4196/kjpp.2022.26.4.277. Korean J Physiol Pharmacol. 2022. PMID: 35766005 Free PMC article.
-
Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.Curr Neuropharmacol. 2015;13(3):395-406. doi: 10.2174/1570159x13999150424113345. Curr Neuropharmacol. 2015. PMID: 26411967 Free PMC article. Review.
-
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications.Dialogues Clin Neurosci. 2018 Mar;20(1):63-73. doi: 10.31887/DCNS.2018.20.1/bpenninx. Dialogues Clin Neurosci. 2018. PMID: 29946213 Free PMC article. Review.
-
Treatment of clozapine-associated weight gain: a systematic review.Eur J Clin Pharmacol. 2015 Apr;71(4):389-401. doi: 10.1007/s00228-015-1807-1. Epub 2015 Jan 28. Eur J Clin Pharmacol. 2015. PMID: 25627831
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials